Switching from originator to biosimilar infliximab (Remsima) in patients with inflammatory bowel disease (IBD)
Phase of Trial: Phase IV
Latest Information Update: 19 Oct 2016
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Pharmacodynamics
- 30 Oct 2015 New trial record
- 27 Oct 2015 Results presented at the United European Gastroenterology Week (UEG Week) 2015 in a satellite symposium, according to Celltrion media release.
- 27 Oct 2015 Results published in the media release.